Clinical investigation of combination therapy with a1 blocker and vibegron for treating overactive bladder in patients with benign prostatic hyperplasia

Clinical investigation of combination therapy with a1 blocker and vibegron for treating overactive bladder in patients with benign prostatic hyperplasia - Efficacy of combination therapy with a1 blocker and vibegron for treating overactive bladder in patients with benign prostatic hyperplasia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039150

Enrollment

Registered

2020-01-27

Start date

2019-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

vibegron 50mg daily in 8 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Overactive bladder after treatment with a1 blocker in BPH patients 2) Total OABSS scores of 3 or more, urinary urgency episodes of 2 per week or more 3) Patients who have provided consent for participation.

Exclusion criteria

Exclusion criteria: 1) Suspect of malignancy 2) Patient with allergy to beta 3 agonists 3) Patient using a1 blocker within 4 weeks 4) Patients whom investigators consider to be ineligible.

Design outcomes

Primary

Measure	Time frame
The change of OABSS score after 8 weeks	—

Secondary

Measure	Time frame
1) The change of IIEF15 score after 8 weeks 2) The change of EHS score after 8 weeks 3) The change of IPSS score after 8 weeks 4) The level of serum free testosterone and CRP	—

Countries

Japan

Contacts

Public ContactAkemi Yamashita

Koto Hospital Department of Urology

akeyamasit@yahoo.co.jp0336852166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026